Chris Nowers, Picture © Cell Medica

Cell Medica Appoints New CEO

Cell Medica, a company active in the development, manufacture and marketing of personalised cellular immunotherapeutics for the treatment of cancer, has appointed Chris Nowers as Chief Executive Officer and Executive Director.

Mr Nowers joins Cell Medica from the cancer immunotherapy company Kite Pharma, where he was Head of Europe and responsible for the full commercialisation of the CAR-T therapy axicabtagene ciloleucel.

Previous to his role at Kite, he has had a career spanning more than 25 years in the biopharma industry. He has held a number of senior leadership roles that included CEO of Avantogen Oncology, General Management roles at Amgen, and senior global and regional commercial leadership roles at Bristol-Myers Squibb (BMS).

“Cell Medica has an exciting array of technologies that will help unlock the potential of personalised cellular immunotherapies for both blood cancers and solid tumours. I look forward to working with the Company’s talented executive and scientific teams to take these promising treatments to patients through clinical development,” Chris Nowers commented.